Citigroup’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-1,390
| Closed | -$5.56K | – | 6202 |
|
|
2025
Q2 | $5.56K | Sell |
1,390
-36,748
| -96% | -$91K | ﹤0.01% | 5267 |
|
|
2025
Q1 | $34.7K | Sell |
38,138
-2,265
| -6% | -$3.14K | ﹤0.01% | 4980 |
|
|
2024
Q4 | $112K | Buy |
40,403
+2,754
| +7% | +$10.5K | ﹤0.01% | 4776 |
|
|
2024
Q3 | $197K | Buy |
37,649
+25,969
| +222% | +$135K | ﹤0.01% | 4352 |
|
|
2024
Q2 | $52.1K | Buy |
11,680
+2,652
| +29% | +$12.9K | ﹤0.01% | 4556 |
|
|
2024
Q1 | $69.2K | Buy |
9,028
+2,287
| +34% | +$12.5K | ﹤0.01% | 4467 |
|
|
2023
Q4 | $28.7K | Buy |
6,741
+6,723
| +37,350% | +$23.9K | ﹤0.01% | 4830 |
|
|
2023
Q3 | $75 | Sell |
18
-10,062
| -100% | -$51.2K | ﹤0.01% | 5473 |
|
|
2023
Q2 | $56.1K | Buy |
+10,080
| New | +$59.6K | ﹤0.01% | 4578 |
|
|
2022
Q3 | – | Sell |
-143
| Closed | -$1K | – | 6069 |
|
|
2022
Q2 | $1K | Sell |
143
-12,374
| -99% | -$53.8K | ﹤0.01% | 6041 |
|
|
2022
Q1 | $51K | Buy |
12,517
+8,853
| +242% | +$52.1K | ﹤0.01% | 4721 |
|
|
2021
Q4 | $25K | Buy |
3,664
+560
| +18% | +$4.84K | ﹤0.01% | 5332 |
|
|
2021
Q3 | $36K | Buy |
3,104
+996
| +47% | +$15.5K | ﹤0.01% | 4921 |
|
|
2021
Q2 | $36K | Buy |
2,108
+863
| +69% | +$15K | ﹤0.01% | 4969 |
|
|
2021
Q1 | $25K | Sell |
1,245
-991
| -44% | -$21.9K | ﹤0.01% | 5107 |
|
|
2020
Q4 | $46K | Buy |
2,236
+1,846
| +473% | +$44K | ﹤0.01% | 6094 |
|
|
2020
Q3 | $10K | Buy |
+390
| New | +$9.69K | ﹤0.01% | 6618 |
|
Citigroup's INZY Position: Q3 2025 in Review
Citigroup sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 1,390 shares — an estimated $5.56K sold.
Citigroup first reported a position in INZY in Q3 2020 and held it in 17 quarters. The position peaked at $197K in Q3 2024. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.
- Citigroup reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
- Citigroup sold 1,390 Inozyme Pharma shares in Q3 2025, an estimated $5.56K.
- Citigroup first reported a position in Inozyme Pharma in Q3 2020 and held it in 17 quarters.
- Citigroup's Inozyme Pharma position peaked at $197K in Q3 2024.
- 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.
Based on Citigroup's 13F filing for Q3 2025, filed 10 Nov 2025.